DE3751527D1 - Zusammensetzungen zur Modulation der Effekten von TNF und IL-1. - Google Patents

Zusammensetzungen zur Modulation der Effekten von TNF und IL-1.

Info

Publication number
DE3751527D1
DE3751527D1 DE3751527T DE3751527T DE3751527D1 DE 3751527 D1 DE3751527 D1 DE 3751527D1 DE 3751527 T DE3751527 T DE 3751527T DE 3751527 T DE3751527 T DE 3751527T DE 3751527 D1 DE3751527 D1 DE 3751527D1
Authority
DE
Germany
Prior art keywords
tnf
modulating
compositions
effects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE3751527T
Other languages
English (en)
Other versions
DE3751527T2 (de
Inventor
David Wallach
Helmut Holtmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Publication of DE3751527D1 publication Critical patent/DE3751527D1/de
Application granted granted Critical
Publication of DE3751527T2 publication Critical patent/DE3751527T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE3751527T 1986-09-10 1987-09-09 Zusammensetzungen zur Modulation der Effekten von TNF und IL-1. Expired - Lifetime DE3751527T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL80005A IL80005A (en) 1986-09-10 1986-09-10 Compositions for modulating the effect of tnf and il-1

Publications (2)

Publication Number Publication Date
DE3751527D1 true DE3751527D1 (de) 1995-10-26
DE3751527T2 DE3751527T2 (de) 1996-02-22

Family

ID=11057124

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3751527T Expired - Lifetime DE3751527T2 (de) 1986-09-10 1987-09-09 Zusammensetzungen zur Modulation der Effekten von TNF und IL-1.

Country Status (9)

Country Link
US (1) US5211945A (de)
EP (1) EP0259863B1 (de)
JP (1) JPH07106986B2 (de)
AU (1) AU603134B2 (de)
CA (1) CA1322713C (de)
DE (1) DE3751527T2 (de)
ES (1) ES2080042T3 (de)
IL (1) IL80005A (de)
ZA (1) ZA876783B (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1329119C (en) * 1988-03-29 1994-05-03 Milton David Goldenberg Cytotoxic therapy
US5120525A (en) * 1988-03-29 1992-06-09 Immunomedics, Inc. Radiolabeled antibody cytotoxic therapy of cancer
EP0393438B1 (de) * 1989-04-21 2005-02-16 Amgen Inc. TNF-Rezeptor, TNF bindende Proteine und dafür kodierende DNAs
US7264944B1 (en) 1989-04-21 2007-09-04 Amgen Inc. TNF receptors, TNF binding proteins and DNAs coding for them
US6221675B1 (en) 1989-04-21 2001-04-24 Amgen, Inc. TNF receptors, TNF binding proteins and DNAs coding for them
US6143866A (en) * 1989-07-18 2000-11-07 Amgen, Inc. Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc A method of producing a recombinant human necrotic factor absorber
US6541610B1 (en) * 1989-09-05 2003-04-01 Immunex Corporation Fusion proteins comprising tumor necrosis factor receptor
DE59010933D1 (de) 1989-09-12 2003-05-08 Hoffmann La Roche TFN-bindende Proteine
US5370870A (en) * 1989-10-06 1994-12-06 Genentech, Inc. Method for protection against reactive oxygen species
US5200176A (en) * 1989-10-06 1993-04-06 Genentech, Inc. Method for protection of ischemic tissues using tumor nerosis factor
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
IL97779A (en) * 1990-04-10 2000-01-31 Genentech Inc Compositions for cytoprotection against radiation and chemotherapy injury or risk thereof
US20030064480A1 (en) * 1990-06-28 2003-04-03 Leander Lauffer Fusion proteins with immunoglobulin portions, the preparation and use thereof
EP0495131B1 (de) * 1990-08-10 1997-05-14 Otsuka Pharmaceutical Co., Ltd. Wirkstoff zur hepatitisverhütung und -behandlung
US6685930B1 (en) * 1991-03-27 2004-02-03 Tanox, Inc. Methods and substances for recruiting therapeutic agents to solid tumors
AU671116B2 (en) * 1992-03-30 1996-08-15 Immunex Corporation Fusion proteins comprising tumor necrosis factor receptor
US5632982A (en) * 1994-06-07 1997-05-27 The Board Of Trustees Of The Leland Stanford Junior University Cytotoxic enhancement of TNF with copper
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
ES2207759T3 (es) 1996-12-06 2004-06-01 Amgen Inc. Terapia de combinacion que utiliza una proteina de union del factor de necrosis tumoral (tnf) en el tratamiento de enfermedades inducidas por el tnf.
US6287558B1 (en) 1997-08-01 2001-09-11 Biohybrio Technologies Llc Devices containing cells or tissue and an agent that inhibits damage by a host cell molecule
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
AU1623300A (en) * 1998-11-13 2000-06-05 Sensor Technologies, Inc. Monodisperse preparations useful with implanted devices

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1265444A (en) * 1983-06-27 1990-02-06 Lloyd J. Old Effect of human tumor necrosis factor and human interferon on human cancer cells and methods
DE3423234A1 (de) * 1984-06-23 1986-02-06 Boehringer Ingelheim International GmbH, 6507 Ingelheim Synergistische mischungen von interferonen und tumor-nekrose-faktor
US4822605A (en) * 1986-02-18 1989-04-18 Exovir, Inc. Compositions and methods employing the same for the treatment of viral and cancerous skin lesions and the like
US4863727A (en) * 1986-04-09 1989-09-05 Cetus Corporation Combination therapy using interleukin-2 and tumor necrosis factor
CA1290249C (en) * 1986-04-09 1991-10-08 Cetus Corporation COMBINATION THERAPY USING INTERLEUKIN-2 AND/OR INTERFERON-.beta. AND TUMOR NECROSIS FACTOR
US4879111A (en) * 1986-04-17 1989-11-07 Cetus Corporation Treatment of infections with lymphokines
US4980160A (en) * 1986-10-16 1990-12-25 Biogen, Inc. Combinations of tumor necrosis factors and anti-inflammatory agents and methods for treating malignant and non-malignant diseases
US4816436A (en) * 1986-10-29 1989-03-28 Immunex Corporation Anti-arthritic use of interleukin-1 proteins
JPH07106158B2 (ja) * 1986-12-04 1995-11-15 サントリー株式会社 抗腫瘍活性を有する新規ポリペプチドおよびその製造法

Also Published As

Publication number Publication date
EP0259863B1 (de) 1995-09-20
EP0259863A3 (en) 1989-11-02
JPS63146830A (ja) 1988-06-18
AU603134B2 (en) 1990-11-08
IL80005A (en) 1992-11-15
US5211945A (en) 1993-05-18
ES2080042T3 (es) 1996-02-01
EP0259863A2 (de) 1988-03-16
AU7820587A (en) 1988-03-17
JPH07106986B2 (ja) 1995-11-15
CA1322713C (en) 1993-10-05
ZA876783B (en) 1988-05-25
IL80005A0 (en) 1986-12-31
DE3751527T2 (de) 1996-02-22

Similar Documents

Publication Publication Date Title
DE3751527D1 (de) Zusammensetzungen zur Modulation der Effekten von TNF und IL-1.
DE68925975D1 (de) Zusammensetzung zur Verhinderung der übertragung von AIDS.
DE3581953D1 (de) Smektische fluessigkristallverbindung und fluessigkristallzusammensetzungen.
DE68922049D1 (de) Pulsbreiten-modulierte Leistungsversorgung mit Unterdrückungsfähigkeit von Modulierungsfrequenzsignalkomponenten von Erdpotentialen.
DE3674642D1 (de) Zur modifizierung von bitumen verwendbare polymerzusammensetzungen und so modifizierte bitumenmassen.
DE3866658D1 (de) Zementzusammensetzungen auf basis von aluminiumphosphat und diese enthaltende lampenverbindungen.
DE3667605D1 (de) Windel zur verhuetung von wundliegen.
DE3687920D1 (de) Elektrooptischer welleneleitermodulator.
DE3680507D1 (de) Verwendung von oxirancarbonsaeuren zur behandlung der hyperlipaemie.
DE3672143D1 (de) Koernige zusammensetzungen von fluorelastomeren.
DE3777878D1 (de) Mittel zur verhinderung des zusammenbackens von duengemitteln.
FR2554933B1 (fr) Modulateur et/ou deflecteur acoustico-optique
DE3579845D1 (de) Fluessigkristall-verbindung und dieselbe enthaltende fluessigkristallzusammensetzung.
ATE79255T1 (de) Wirkstoffe zur verhuetung von tumormetastasen.
DD129729A5 (de) Mittel zur wachstumsverzoegerung und zur entblaetterung von pflanzen
DE3778104D1 (de) Zusammenstellung von hydroxylapatite-teilchen und diese enthaltende fluessigkeitschromatographie-saeule.
DE3766153D1 (de) Vorbeugung der geruchsabschwaechung von mit organoschwefelverbindungen odorisiertem fluessiggas.
DE3688448D1 (de) Elimination von feldinduzierten instabilitaeten in elektrooptischen modulatoren.
DE3682155D1 (de) Fluessigkristall-alkoxycarbonyloxybenzoesaeurederivate und zusammensetzung.
DE3670757D1 (de) Zusammensetzung zur erhoehung der quantitaet und der qualitaet von pflanzenfruechten und -blueten.
ATA196785A (de) Einrichtung zur nutzung von ueberschussdampf
ATA311386A (de) Einrichtung zur kompensation der hochschlagund rueckstossenergie von faustfeuerwaffen
DD280029A1 (de) Mittel zur erhoehung der stresstoleranz von kulturpflanzen
DE3672039D1 (de) Einrichtung zur filtrierung und transienten stabilisierung der netzspannung.
DD136162A1 (de) Seitenablauf zur entwaesserung von verkehrsflaechen und dergleichen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition